Trosunilimab clinical trials
Also written ABBV-382.
How each study uses trosunilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trosunilimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Risankizumab (2) · ABBV-701 (1) · Lutikizumab (1) · ABBV-8736 (1) · Budigalimab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test trosunilimab.
Studies
Open first, then newest update. How each study uses trosunilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Assess How Intravenous and Subcutaneous Administrations of Trosunilimab Move Through the Body of Healthy Adult ParticipantsRecruitingPhase 1AbbVieNCT07925983Written as Trosunilimab
- Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingPhase 2AbbVieNCT07697456Written as Trosunilimab
- Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingPhase 2AbbVieNCT06548542Written as Trosunilimab
- A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382TerminatedPhase 2AbbVieNCT06032546Written as ABBV-382
- A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese VolunteersCompletedPhase 1AbbVieNCT06632938Written as ABBV-382
- Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)CompletedPhase 1AbbVieNCT04554966Written as ABBV-382
What changed recently
From the registry's own updates since Oct 18, 2026.
Results posted1
Newly registered1
Codes
What other systems call trosunilimab · ClinicalTrials.gg INT017200
- UNII (FDA) LNN5K7KB5RTROSUNILIMABOne source FDA
- NCI Thesaurus C207007TrosunilimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LNN5K7KB5R | TROSUNILIMAB | One source FDA |
| NCI Thesaurus | C207007 | Trosunilimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.